A second generation of precision oncology. From Basel.
Lumen develops targeted drugs for solid tumours with underserved mutation profiles. Lead programme LUM-201 completes Phase Ib in Q1/27. We are opening a Series A and looking for a lead investor.
Three numbers that carry everything.
A focused Series A for one clearly defined inflection point: the Phase Ib readout of the lead programme.
Science we can put our hands on.
Lead programme LUM-201 targets KRAS and BRAF mutations in solid tumours. Our own companion diagnostic, our own patents, our own preclinical data.
Drug plus diagnostic.
The costliest mistake in oncology is the wrong patient group in the wrong trial.
Oncology pipelines rarely fail on the drug, they fail on patient selection. We build the drug and the companion diagnostic together, from day one.
Oncology is the largest therapy class in the world.
Researched market context, backed by sources. Precision oncology grows structurally faster than the overall market.
- 1
Rising cancer burden
Cancer remains one of the leading causes of death worldwide, with incidence still rising.[1]
- 2
From organ to mutation profile
Precision oncology shifts treatment from the tumour organ to the genetic mutation profile.[2]
- 3
Largest, fastest therapy class
By spend, oncology is the largest and fastest-growing therapy class.[3]
Market context, researched. Full references in the Sources section.
Targeted oncology: global, 2024 to 2032.
CAGR 14.2 %. Lumen’s addressable market (KRAS + BRAF) grows faster than the overall segment.
Own modelling based on the market sources in the Sources section.
Programme status by phase progress.
Three assets, one shared target profile. Each programme has a defined next milestone.
EUR 28 M: where the capital goes.
The lion’s share goes into clinical development of the lead programme. The round funds 30 months of runway, well past the Phase Ib readout.
- Clinical trials14.6 M
- Preclinical LUM-1155.0 M
- Companion Dx3.4 M
- R&D staff3.1 M
- G&A, legal, IP1.9 M
Why Lumen.
A team that has taken this science into the clinic before. Four numbers on the substance behind the pitch.
Four milestones to the inflection point.
Each milestone de-risks the asset and lifts the valuation. The Series A carries the programme safely past the Phase Ib readout.
- 1
Q4 2026: IND LUM-115
Filing in the US, EMA scientific advice in parallel.
- 2
Q1 2027: Phase Ib readout LUM-201
First efficacy data, dose escalation completed.
- 3
Q3 2027: Phase IIa start
Multicentre trial in EU and US, around 120 patients.
- 4
Q2 2028: Series B
On the Phase IIa interim, planned EUR 80 to 120 M.
We are looking for a lead for 12 to 15 M.
- 1
NDA & data room
Full access within 24 hours.
- 2
Management deep-dive
90 minutes with CEO, CSO and Head of Clinical.
- 3
Term sheet
Lead term sheet by end of Q1/27, closing Q2/27.
References and market sources.
Every market claim above is backed by publicly available industry sources.
- 1Global Cancer Observatory, Cancer Burden
- 2The promise of precision oncology
- 3Global Oncology Trends